196 related articles for article (PubMed ID: 23151945)
1. Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.
Alderson KL; Luangrath M; Elsenheimer MM; Gillies SD; Navid F; Rakhmilevich AL; Sondel PM
Cancer Immunol Immunother; 2013 Apr; 62(4):665-75. PubMed ID: 23151945
[TBL] [Abstract][Full Text] [Related]
2. Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.
Johnson EE; Buhtoiarov IN; Baldeshwiler MJ; Felder MA; Van Rooijen N; Sondel PM; Rakhmilevich AL
J Immunother; 2011 Jan; 34(1):76-84. PubMed ID: 21150715
[TBL] [Abstract][Full Text] [Related]
3. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
[TBL] [Abstract][Full Text] [Related]
4. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
5. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.
Lum HD; Buhtoiarov IN; Schmidt BE; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Leukoc Biol; 2006 Jun; 79(6):1181-92. PubMed ID: 16565324
[TBL] [Abstract][Full Text] [Related]
6. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
[TBL] [Abstract][Full Text] [Related]
7. A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.
Federico SM; McCarville MB; Shulkin BL; Sondel PM; Hank JA; Hutson P; Meagher M; Shafer A; Ng CY; Leung W; Janssen WE; Wu J; Mao S; Brennan RC; Santana VM; Pappo AS; Furman WL
Clin Cancer Res; 2017 Nov; 23(21):6441-6449. PubMed ID: 28939747
[No Abstract] [Full Text] [Related]
8. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.
Schettini J; Kidiyoor A; Besmer DM; Tinder TL; Roy LD; Lustgarten J; Gendler SJ; Mukherjee P
Cancer Immunol Immunother; 2012 Nov; 61(11):2055-65. PubMed ID: 22543528
[TBL] [Abstract][Full Text] [Related]
9. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.
Buhtoiarov IN; Lum H; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Immunol; 2005 May; 174(10):6013-22. PubMed ID: 15879094
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.
Qu X; Felder MA; Perez Horta Z; Sondel PM; Rakhmilevich AL
Int Immunopharmacol; 2013 Dec; 17(4):1141-7. PubMed ID: 24201083
[TBL] [Abstract][Full Text] [Related]
11. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.
Nguyen R; Houston J; Chan WK; Finkelstein D; Dyer MA
Cancer Immunol Immunother; 2018 Apr; 67(4):615-626. PubMed ID: 29327110
[TBL] [Abstract][Full Text] [Related]
12. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
13. 64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma.
Vavere AL; Butch ER; Dearling JL; Packard AB; Navid F; Shulkin BL; Barfield RC; Snyder SE
J Nucl Med; 2012 Nov; 53(11):1772-8. PubMed ID: 23064212
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.
Buhtoiarov IN; Sondel PM; Wigginton JM; Buhtoiarova TN; Yanke EM; Mahvi DA; Rakhmilevich AL
Immunology; 2011 Feb; 132(2):226-39. PubMed ID: 21039467
[TBL] [Abstract][Full Text] [Related]
16. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.
Buhtoiarov IN; Sondel PM; Eickhoff JC; Rakhmilevich AL
Immunology; 2007 Mar; 120(3):412-23. PubMed ID: 17163960
[TBL] [Abstract][Full Text] [Related]
17. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.
Rakhmilevich AL; Buhtoiarov IN; Malkovsky M; Sondel PM
Cancer Immunol Immunother; 2008 Aug; 57(8):1151-60. PubMed ID: 18214476
[TBL] [Abstract][Full Text] [Related]
18. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
[TBL] [Abstract][Full Text] [Related]
19. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.
Liu C; Lewis CM; Lou Y; Xu C; Peng W; Yang Y; Gelbard AH; Lizée G; Zhou D; Overwijk WW; Hwu P
J Immunother; 2012 Apr; 35(3):276-82. PubMed ID: 22421945
[TBL] [Abstract][Full Text] [Related]
20. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]